Novel immune checkpoints beyond PD-1 in advanced melanoma

Over the past decade, immune checkpoint inhibitors (ICIs) successfully shaped the therapeutic landscape of malignant tumors. The most broadly studied and first immune checkpoint targets were cytotoxic T lymphocyte-associated antigen‑4 (CTLA-4), programmed cell death protein‑1 (PD-1) and its ligand (PD-L1). The binding of CTLA‑4 (CD152) to the ligands CD80 (B7-1) and CD86 (B7-2) delivers a negative signal to T cell activation [1], whereas the binding of PD‑1 (CD279) to its ligands PD-L1 and PD-L2 (CD273, B7-DC) suppresses the activation and function of T cells, thereby downregulating adaptive immune response [2, 3]. Ipilimumab, a monoclonal antibody (mAb) against CTLA‑4, was the first ICI approved by the United States Food and Drug Administration (FDA) in 2011 after demonstrating a survival benefit for patients with advanced melanoma over the chemotherapeutic dacarbazine. Pembrolizumab, the first humanized mAb against PD‑1, gained initial global approval for patients with unresectable or metastatic melanoma by the FDA in 2014 [4]. Since then, the indication of those mAbs to several other tumor entities, and the list of approved ICIs against PD-1/PD-L1 or CTLA‑4 have expanded [5]. The current benchmark for efficacy in melanoma therapy is the combinational therapy of anti-CTLA‑4 and anti-PD‑1 agents [6]. However, roughly half of all patients will not benefit from ICIs, and therefore identification of predictive markers allowing patient stratification regarding first- and second-line treatment strategies and avoiding toxicity of ineffective therapy is of immense clinical interest [7, 8]. The search for new potential targets and pathways has already resulted in a new portfolio of targets for novel treatment options, mostly tested in combination with PD‑1 inhibitors. Molecules targeting inhibitory pathways such as the type I transmembrane glycoproteins lymphocyte activation gene 3 protein (LAG-3), T cell immunoglobulin mucin receptor 3 (TIM-3), T cell immunoglobulin mucin receptor 3 (TIGIT) or B7 homolog 3 (B7-H3) are being investigated, as well as agonists of stimulatory checkpoint pathways, such as OX-40, the inducible T cell co-stimulator (ICOS), the glucocorticoid-induced TNFR-related protein (GITR), 4‑1BB and CD40 (Fig. 1, Table 1).

After CTLA‑4 and PD‑1, lymphocyte activation gene 3 protein (LAG-3) was the third inhibitory receptor targeted with mAbs in clinical trials. LAG‑3 is a T cell-associated inhibitory checkpoint protein and member of the immunoglobin (Ig) superfamily, co-expressed with PD‑1 and usually present on T cells, B cells, dendritic cells (DCs) and natural killer cells (NK cells) [9]. It is responsible for regulating immune tolerance and T cell homeostasis by its inhibitory effect on effector T cell proliferation and enhancing regulatory T cell function [9, 10]. Pre-clinical studies have shown that dual PD‑1 and LAG‑3 blockade synergistically stimulate T cell responses and decrease tumor burden more than either agent alone [11]. In addition, the efficiency of the LAG‑3 antibody relatlimab seems to be increased in tumors with higher LAG‑3 expression, indicating that it might be used as a biomarker [6, 12].

The T cell immunoglobulin mucin receptor 3 (TIM‑3, CD366) is a type I transmembrane protein that can be found on a variety of immune cells and its expression was also demonstrated on melanoma tumor-infiltrating lymphocytes (TILs) [13‐15]. Animal models of advanced melanoma demonstrated that blocking TIM‑3 reverses T cell exhaustion and dysfunction [10, 14‐16]. Anti-TIM‑3 antagonist antibodies, like cobolimab, are currently under investigation in phase II clinical studies in combination with other checkpoint inhibitors or as a bispecific antibody (anti-PD‑1 and anti-TIM-3) in a phase I multiple-ascending dose study.

Another inhibitory receptor is the T‑cell immunoreceptor with Ig and ITIM domains (TIGIT). This transmembrane glycoprotein receptor is expressed not only on T cells, regulatory T cells (Tregs) and NK cells, but also highly expressed on melanoma cells, DCs and monocytes within the melanoma tumor microenvironment (TME) [15, 17, 18]. TIGITs immunosuppressive effects are mediated through a decreased release of pro-inflammatory cytokines and an increased release of IL-10 [19]. Vibostolimab, an anti-TIGIT antibody, is currently under investigation in a number of sub-studies to an umbrella study, testing experimental treatments for melanoma.

The B7 homolog 3 (B7-H3, CD276) protein is a type I transmembrane protein commonly expressed on antigen presenting cells (APCs), NK cells, tumor cells and tumor endothelial cells, belonging to the B7-CD28 pathway family. Its overexpression is frequent in multiple malignancies including melanoma, correlating with poor prognosis [20, 21]. Little is known about the molecular mechanisms underlying B7-H3 functions and its receptor(s) have not yet been identified. Research demonstrates that the B7-H3 pathway promotes cancer aggressiveness, while exerting inhibitory function on T cell activation, proliferation and cytokine production [20, 21]. This indicates that besides enhancing innate immunological responses against malignancies, B7-H3 blockade might also directly affect tumor behavior. The safety of the mAb enoblituzumab in combination with pembrolizumab on B7-H3 expressing melanomas and other cancers is currently evaluated. When combined with chemotherapy or other ICIs, it appears to have a synergistic effect [20, 21].

The B and T cell lymphocyte attenuator (BTLA, CD272) expressed by the majority of lymphocytes is an inhibitory receptor, structurally and functionally related to CTLA‑4 and PD‑1. Binding of BTLA to its ligand herpes virus entry mediator (HVEM) leads to an inhibition of T and B cell activation, proliferation and cytokine production [20, 22]. By expressing HVEM, melanoma cells have been shown to exploit this pathway and high levels of BTLA/HVEM correlate with progression and poor prognosis, making this pathway a promising target for checkpoint blockade [23]. The first anti-BTLA mAb approved for clinical trials is currently being assessed regarding its safety and tolerability as monotherapy in advanced malignancies.

The V‑domain Ig suppressor of T cell activation (VISTA) is a type I transmembrane protein and B7 family member. It is constitutively expressed on multiple immune cell types, mainly on myeloid cells including neutrophils, monocytes, macrophages and DCs, and can also be found on TILs [24, 25]. Structural analysis suggests that VISTA has the potential to function as a receptor and a ligand [26]. Furthermore, evidence indicates that VISTA could exert a dual role, stimulatory for APCs on the one side and inhibitory for T cells on the other [20]. Recently, VSIG‑3 was reported as a binding partner of VISTA [27]. In pre-clinical studies, VISTA blockade has demonstrated improved infiltration, proliferation and effector function of TILs within the TME, thereby altering the suppressive properties of the TME [28, 29].

For optimal cancer control it may not be sufficient to target negative regulatory pathways alone, but may require the activation of co-stimulatory pathways either alone or in combination with checkpoint blockade to enhance the immune response.

OX-40 (CD134, TNFRSF4) is a T cell co-stimulatory protein and member of the tumor necrosis factor receptor superfamily (TNFRSF). It is primarily expressed on activated T cells and APCs, but it is also expressed at high levels on tumor resident Tregs [30]. OX-40 agonism leads to an increase in the number of activated T cells and those cells gaining effector function, while the induction of Tregs in the periphery is suppressed [31].

Interactions of OX-40 and its ligand on activated T cells increase proliferation, effector and cytotoxic function and cytokine production of those T cells, among other features [32]. Several OX-40 agonist antibodies are investigated in clinical phase I and II trials. Increased OX-40 expression on TILs in cutaneous melanoma is associated with improved prognosis [33].

Another promising immunotherapy target is the glucocorticoid-induced TNFR-related protein (GITR), stimulating the acquired and innate immunity. It is highly expressed on Tregs and activated upon binding to its ligand GITRL, mainly expressed on APCs and endothelial cells. This exerts dual effects, down-regulation of Tregs and up-regulation of CD8+ effector cells while extending their survival [15, 34, 35]. Anti-tumor activity of agonistic anti-GITR antibodies has already been demonstrated in mouse models and is currently evaluated in phase I and II clinical trials in melanoma and other tumor types [36].

The inducible T cell co-stimulator, short ICOS (CD278), is an immune checkpoint protein structurally and functionally related to CD28, a T cell specific cell-surface receptor like CTLA‑4, and an important regulator of the immune system. ICOS is expressed on activated cytotoxic T cells, Tregs, NK cells and other types of T cells. It enhances all basic T cell functions to a foreign antigen like proliferation, secretion of cytokines and mediators up-regulating cell–cell interaction and supporting antibody secretion by B cells [37]. Up-regulation of ICOS can be detected in activated T cells, especially after anti-CTLA‑4 therapy, where it can serve as a biomarker indicating the binding of anti-CTLA‑4 antibodies to their targets. Increased expression on circulating T cells after ipilimumab therapy has been associated with improved clinical outcomes [38, 39]. Due to the upregulation of ICOS after anti-CTLA‑4 therapy, the combination of those targets can achieve potent synergistic effects [20, 37].

Another important regulator of immune response and member of the TNFRSF is 4‑1BB (CD137, TNFRSF9). This co-stimulatory molecule is expressed on innate and adaptive immune cells and triggers proliferation and prolonged survival of CD8+ effector T cells and NK cells upon binding to its ligand 4‑1BBL [20, 40]. Anti-4-1BB antibody blockade has been shown to induce potent anti-tumor T cell responses by promoting CD8+ T cell proliferation, enhancing T cell receptor (TCR) signaling and inducing immunologic memory [41, 42]. Several pre-clinical agonistic antibodies are currently under investigation, like utomilumab, in a phase II study in melanoma [41].

An additional member of the TNF family and co-stimulatory immune checkpoint receptor is the glycoprotein CD27 expressed on T cells, NK cells and Tregs. Its ligand is CD70, which is expressed on DCs, activated B and T cells [43]. When CD27 is bound by CD70, CD8+ T cell activation, survival and effector function are enhanced. To prevent unwanted stimulation of T cells, CD70 is usually not available. In this case, varlilumab or other mAbs can substitute and activate T cells receiving TCR stimulation [44].

Immune co-stimulatory receptor CD40 (TNFRSF5) is also part of the TNFRSF and expressed on APCs, including DCs, B cells, macrophages and monocytes. It plays a key role in the activation of the immune system, while binding to its ligand CD40L (CD154) on T cells [20]. Binding of CD40 leads to increased priming and activation of CD8+ T cells, mediated through increased major histocompatibility complex (MHC) surface expression on DCs, production of pro-inflammatory cytokines and B cell proliferation [15, 45]. Healthy tissue exhibits comparatively low to no CD40 expression, indicating strong potential as a cancer-specific immunological target [46]. Several clinical trials are studying the effects of CD40 as monotherapy or in combination.

Besides targeting immune checkpoints and thereby inducing inhibitory or co-stimulatory immune responses, further research interest is aimed at other promising pathways and mechanisms.

Modulating the TME through indoleamine 2,3-dioxygenase 1 (IDO1) is one of those approaches. IDO1 is a tryptophan catabolizing and IFN-inducible enzyme, promoting tumor-mediated immunosuppression. It thereby inhibits effector T cells and NK cells and activates Tregs and myeloid-derived suppressor cells [15, 47]. IDO1 is overexpressed in several malignancies including melanoma, while inhibition shifts the TME from a tumor-promoting inflammatory to an immune stimulating state [48]. Especially in melanoma, previous research established a relationship between CTLA‑4, PD‑1 and IDO1 associated with poor prognosis, independent of disease stage, making IDO1 a potential target for further investigation [15, 49]. However, a phase III study showed no survival benefit from enhancing anti-PD‑1 therapy by IDO1 inhibition [50].

Another major factor in the immunosuppressive TME is the adenosine pathway, which is mediated by ectonucleotidases, like CD39 and CD73, and adenosine receptors, like A2AR. In melanoma, increased CD73 (ecto-5′-nucleotidase) expression correlates with a more aggressive, invasive phenotype and can be detected in over 50% of the metastases [51], while CD39 is overexpressed earlier in tumor development, potentially influencing the differentiation of melanocytes to melanoma cells [15]. In pre-clinical models, CD73 blockade showed inhibition of metastasis formation and improved anti-tumor immunity [52]. A first-in-human study is currently evaluating the safety of a small molecule inhibitor targeting CD73 as monotherapy or in combination with pembrolizumab in patients with melanoma and other advanced solid malignancies.

Targeting TLRs aims at a family of specialized receptors, stimulating immune responses to pathogen-associated molecular patterns (PAMPs). Among those, TLR9 has been shown to induce potent anti-tumor responses by stimulating innate and adaptive immune responses [53], ultimately leading to strong CD4+ and CD8+ T cell responses that may intensify the efficacy of ICIs [54]. Clinical activity of TLR9 has been shown in advanced melanoma patients unresponsive to PD-(L)1 inhibition.

Oncolytic peptides are cytotoxic chemotherapeutic peptides, injected intratumorally and thereby limiting systemic toxicities as well as their application to disseminated malignancies [20]. Injection of the lactoferrin-derived lytic peptide ruxotemitide leads to tumor antigen release followed by increased TIL activity and CTLA‑4 expression, suggesting administration in conjunction with anti-CTLA‑4 agents [55].

IL‑2 is nothing new and is considered the first effective immunotherapy in cancer [56]. Due to severe toxicities, IL-2R agonists have been developed to potentiate and prolong IL‑2 anti-tumor effects, thereby allowing lower doses. Bempegaldesleukin, an engineered cytokine specifically stimulating through IL-2Rβ (CD122), is currently being investigated in combination with nivolumab in a phase III clinical trial in melanoma. Pegilodecakin, the PEGylated form of IL-10, is under investigation in regard to safety and tolerability in a phase I study. Also for IL-10, a combination with PD‑1 seems reasonable due to both receptors being upregulated on TILs [20].

Promising results have also been shown with histone deacetylase (HDAC) inhibitors and pembrolizumab in patients with unresectable or metastatic melanoma that progressed during or after anti-PD‑1 therapy. Histone acetylation and deacetylation play a key role in regulating gene transcription, and inhibition of this process has emerged as a potential anticancer therapeutic in various malignancies [15].

Another emerging field of research focusses on intra-tumoral agents, like the stimulator of interferon genes (STING). STING is a transmembrane protein that is activated by cyclic dinucleotides and plays an important role in innate immunity by stimulating type 1 IFN‑1 and DC activation [15]. In mouse models, intra-tumoral injection of the dinucleotide caused regression of the injected and untreated lesions. Pre-clinical data demonstrates that tumor antigen recognition in melanoma can be enhanced by restoring MHC class I surface expression through agonist-induced activation of STING signaling [57]. This suggests that synthetic cyclic dinucleotides activating the STING pathway should be considered as a therapeutic intervention and further investigated. Phase I trials are currently testing stimulators of STING.

Understanding the immunobiology of tumors and therapeutic resistance will remain a major challenge for the future. The aim is to develop effective immunotherapies tailored to individual subgroups of patients, especially those not achieving long-term clinical benefit. Omics-based strategies utilizing the respective bioinformatics could deliver a potential breakthrough in this ongoing (re)search in precision medicine (Fig. 2). To understand the complexity of the tumor-immune microenvironment consisting of interactions between multiple cell types, omics-guided approaches can help in assessing for instance the TME, immune system and cancer cells. Microbiome strategies, representing the next wave of treatment approaches in immuno-oncology, will likely enrich this dynamic therapeutic landscape even further. The results from pre-clinical research and subsequently clinical studies will provide potential predictive biomarkers, novel treatment options and pharmacodynamic markers to guide treatment decisions for each individual patient. Ultimately, a combination of immunotherapies or integration of immunotherapy with non-immunotherapies will likely succeed over single agent approaches, given the complexity of the immune response.